XDEMVY
Peaklotilaner ophthalmic solution
NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
Drug data last refreshed 52m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XDEMVY is a novel ectoparasiticide ophthalmic solution containing lotilaner, approved July 2023 for direct ocular application. It represents the first and currently only topical treatment in its pharmacologic class for parasitic eye infections. The drug works by targeting ectoparasites through a localized ocular delivery mechanism.
$7.0MPart D
Peak12.2 years to LOEEarly-stage peak commercial phase with minimal competitive pressure suggests a specialized market focused on niche patient populations; commercial team remains lean but growing.
Mechanism of Action
Pharmacologic Class:
Ectoparasiticide
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
XDEMVY represents a specialized career opportunity in a novel therapeutic space with zero competition, offering unique expertise development in ophthalmic ectoparasiticide treatment. Career progression is tied to indication expansion strategy and patent portfolio extension rather than competitive market share gains.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.